2018 American Transplant Congress
Characterization of Mesenchymal Stem Cell Phenotype and Its Immunomodulatory Effects during Allo-Specific T Cell Immune-Responses
Department of Surgery, Duke University Medical Center, Durham, NC.
Mesenchymal stem cells (MSCs) have been suggested play an important role in modulating cell-mediated immunity. In the setting of transplantation, allogeneic MSCs could mediate suppressive…2018 American Transplant Congress
The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients
1Athena Study Group, Germany; 2Athena Study Group, France; 3Novartis, Pharma, Germany.
The ATHENA study was set up to compare efficacy and safety of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A [CyA] vs. a mycophenolic…2018 American Transplant Congress
Metabolic Therapy as a Platform for CTLA4Ig Costimulation Blockade in Preventing Allograft Rejection
The backbone of current immunosuppression regimens remains calcineurin inhibitors (CNI) in association with steroids, mycophenolate mofetil or mTOR inhibitors. However, their long-term administration is associated…2018 American Transplant Congress
Clinical Impact of Denovo or Recurrent Donor Specific Antibodies in the First Year Post Kidney Transplant in Patients on Early Steroid Withdrawal Immunosupression Regimen
Division of Renal Disease and Hypertension, Indiana University Health, Indianapolis, IN.
Background: Immunologic risk monitoring of recipients of kidney transplant(Tx) using donor specific antibodies (DSA) has become a standard practice in most Tx centers in the…2018 American Transplant Congress
Association of CYP3A5*3*6*7 Metabolic Composites to Tacrolimus Pharmacokinetics in African American and Caucasian Renal Transplant Recipients
Background: Interpatient variability in tacrolimus pharmacokinetics(PK) is due primarily to metabolism by cytochrome P-450 3A5(CYP3A5) isoenzymes. African Americans(AA) require higher tacrolimus doses to achieve comparable…2018 American Transplant Congress
Hyperkalemia in the Early Post Renal Transplant Period
Hyperkalemia is a recognized and potentially life threatening complication post renal transplantation. Aside from delayed graft function, the most frequent culprit identified is pharmacotherapy. Many…2018 American Transplant Congress
Association between Everolimus Trough Levels, Onset of Related Adverse Events, and Treatment Discontinuation after Liver Transplantation: 24-Month Results from the H2304 Study
Purpose: Evaluation of mammalian target of rapamycin inhibitor (mTORi)-related adverse events (AEs) and drug trough levels (C0) at onset may aid their management in liver…2018 American Transplant Congress
Greater Susceptibility for Metabolic Syndrome in Pediatric Transplant Recipients – A Case-Control Study
Introduction. Metabolic syndrome not only contributes to an increased risk for cardiovascular sequelae but is also associated with impaired graft function and lower graft survival…2018 American Transplant Congress
Simplified Once-Daily Immunosuppressive Regimen for Stable Kidney Recipients
Background. Many immunosuppressive drugs are prescribed as twice-daily dosing. Simplified once-daily dosing of the entire drug regimen can improve treatment satisfaction for patients. We examined…2018 American Transplant Congress
Belatacept and Tacrolimus Corticosteroid-Free Regimens Lead to Elevated Mycophenolic Acid Exposure at 1 and 3 Months after Kidney Transplantation
Mycophenolate mofetil (MMF) is generally administered as a fixed dose. Studies have shown a relationship between MPA exposure (MPAAUC) but no data evaluates this relationship…
- « Previous Page
- 1
- …
- 65
- 66
- 67
- 68
- 69
- …
- 138
- Next Page »